Abstract:Anaplastic lymphoma kinase (ALK)-driven lung cancer represents a critical therapeutic target, demanding innovative approaches for the identification of effective inhibitors. Anaplastic lymphoma kinase (ALK), a key protein involved in the pathogenesis of ALK-driven lung cancers, has been the focus of extensive drug discovery efforts. This study employed a comprehensive computational drug discovery approach, integrating virtual screening with the Lipinski filter, re-docking, molecular dynamics (MD) simulations, and free energy calculations to identify potential inhibitors from a natural compound library. Utilizing the MTiOpenScreen web server, we screened for compounds that exhibit favorable interactions with ALK, resulting in 1227 compounds with virtual screening scores ranging from - 10.2 to - 3.7 kcal/mol. Subsequent re-docking of three selected compounds (ZINC000059779788, ZINC000043552589, and ZINC000003594862) and one reference compound against ALK yielded docking scores - 10.4, - 10.2, - 10.2, and - 10.1 kcal/mol, respectively. These compounds demonstrated promising interactions with ALK, suggesting potential inhibitory effects. Advanced analyses, including MD simulation and binding free energy calculations, further supported the potential efficacy of these compounds. MD simulations, particularly the root mean square deviation (RMSD) and root mean square fluctuation (RMSF) analyses, revealed that compounds ZINC000059779788 and ZINC000003594862 achieved better stability compared to compound ZINC000043552589. These stable conformations suggest effective binding over time. Free energy calculations using the MM/GBSA method showed that ZINC000059779788 had the most favorable binding energy, indicating a strong and stable interaction with the ALK protein. The promising computational findings from this study emphasize the necessity for additional experimental testing to verify the therapeutic efficacy of these natural compounds for treating lung cancers.

Discovery of novel chemotype inhibitors targeting Anaplastic Lymphoma Kinase receptor through ligand-based pharmacophore modelling

Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.

Mutant anaplastic lymphoma kinase inhibitor identification by integrated in silico approaches

Discovery of anaplastic lymphoma kinase inhibitors from natural product library: A holistic in silico approach

3D-Qsar and Molecular Fragment Replacement Study on Diaminopyrimidine and Pyrrolotriazine Alk Inhibitors

Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors

Ligand-based pharmacophore modeling and machine learning for the discovery of potent aurora A kinase inhibitory leads of novel chemotypes

Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)

Selective Mechanisms and Molecular Design of 2,4 Diarylaminopyrimidines As ALK Inhibitors.

Design, Synthesis and Pharmacological Evaluation of 2-(Thiazol-2-amino)-4-arylaminopyrimidines As Potent Anaplastic Lymphoma Kinase (ALK) Inhibitors

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib.

Natural product-derived ALK inhibitors for treating ALK-driven lung cancers: an in silico study

Discovery of new STAT3 inhibitors as anticancer agents using ligand-receptor contact fingerprints and docking-augmented machine learning

An Interaction Map of Small-Molecule Kinase Inhibitors with Anaplastic Lymphoma Kinase (ALK) Mutants in ALK-positive Non-Small Cell Lung Cancer

In Silico Exploration of Novel EGFR Kinase Mutant-Selective Inhibitors Using a Hybrid Computational Approach

Design, Synthesis and Biological Evaluation N2-(2-alkyoxy-6-aliphatic Aminopyridin-3-yl)-2,4-diaminepyrimidine Derivatives Bearing Acylamino or DBTD ‘head’ As Potential ALK Inhibitors

Identification of natural product as selective PI3Kα inhibitor against NSCLC: multi-ligand pharmacophore modeling, molecular docking, ADME, DFT, and MD simulations

Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors

Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer

Inhibitors of the anaplastic lymphoma kinase

Synthesis And Evaluation Of Novel 2,4-Diaminopyrimidines Bearing A Sulfoxide Moiety As Anaplastic Lymphoma Kinase (Alk) Inhibition Agents